The company introduced 100 mg Artesunate Rectocaps/Rectal Artesunate Suppositories (RAS), a life-saving, pre-referral intervention for the management of malaria in children.
The company's RAS 100 mg was recently added to the Global Fund expert review panel's list of quality-assured medicines, while the process of WHO pre-qualification of this medicine moves through its final stages.
Also Read
The Mumbai-based company's product contains 100 mg of Artesunate and is indicated in children from 6 months to 6 years.
It was developed with the support of MMV (with UNITAID financing) and will now soon be available in four sub-Saharan countries.
Cipla shares today ended 0.80 per cent down at Rs 565 on the BSE.